Regorafenib Monotherapy as Second-Line Treatment for RAS-Mutant Advanced Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study
ESMO Open 2023 Jan 03;8(1)100748, C Cardone, A De Stefano, G Rosati, A Cassata, L Silvestro, M Borrelli, E Di Gennaro, C Romano, A Nappi, N Zanaletti, F Foschini, R Casaretti, F Tatangelo, S Lastoria, M Raddi, D Bilancia, V Granata, S Setola, A Petrillo, C Vitagliano, P Gargiulo, L Arenare, A Febbraro, E Martinelli, F Ciardiello, P Delrio, A Budillon, MC Piccirillo, A AvalloneFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.